Effect of Antiplatelet Therapy on Cognition After Aneurysmal Subarachnoid Hemorrhage

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04548401

Enrollment

200

Registered

2020-09-14

Start date

2019-11-01

Completion date

2021-12-31

Last updated

2020-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aneurysmal Subarachnoid Hemorrhage

Brief summary

Deficits in memory, executive function, and language are common cognitive sequelae of aneurysmal subarachnoid hemorrhage (aSAH). Previous study demonstrated that post-treatment antiplatelet therapy reduced risk for delayed cerebral ischemia caused by aSAH. However, the effect of antiplatelet therapy on cognition after aSAH is unclear. The aim of this study was to assess the effect of antiplatelet therapy on cognition after aSAH.

Interventions

DRUGAntiplatelet Drug

aspirin and/or clopidogrel or ticagrelor

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Inclusion criteria

* 1\. Patients with SAH in whom the aneurysm was proven by conventional angiography; 2. Baseline Hunt-Hess grade I-III; 3. patients received endovascular treatment

Exclusion criteria

* 1\. Hunt-Hess grade IV-V; 2. Non-aneurysmal SAH; 3. Dementia in other diseases; 4. Lacking of 6-8 month MoCA evaluation.

Design outcomes

Primary

Measure	Time frame
Montreal Cognitive Assessment (MoCA) Test	6-8 months

Countries

China

Contacts

Primary ContactZhen Yu Jia, MD.

zhenyu_jia@sina.com+86 13770918208

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026